CD8 engineered cytotoxic T cells reprogram melanoma tumor environment

Area of Science:

• Immunology
• Cancer Immunology
• T cell biology

Background:

• Cytotoxic T lymphocytes (CTL) are crucial for anti-tumor immunity.
• CD8β deficiency impairs CTL function, including calcium and NFAT signaling.
• Restoring CD8β can potentially enhance CTL-mediated anti-tumor responses.

Purpose of the Study:

• To investigate the therapeutic potential of CD8β-restored CTL (CD8βR) in a tumor model.
• To determine if CD8βR CTL can reprogram the tumor microenvironment and induce endogenous anti-tumor immunity.

Main Methods:

• Generating GP33-specific CTL from CD8β-deficient mice transduced with CD8β (CD8βR).
• Transferring CD8βR CTL into B16-GP33 tumor-bearing mice.
• Analyzing tumor infiltration, immune cell populations (MDSCs, Treg, T helper cells), antigen-presenting cells, and endogenous CTL responses.

Main Results:

• CD8βR CTL exhibited potent FasL-mediated cytotoxicity and IFNγ, CXCL9, and CXCL10 responses.
• Adoptive transfer of CD8βR CTL led to significant T cell infiltration and reduction of immunosuppressive cells (MDSCs, Treg, IL-17+ T helper cells).
• CD8βR CTL promoted maturation of antigen-presenting cells and induced endogenous B16 melanoma-specific CTL, leading to tumor eradication.

Conclusions:

• The combination of enhanced cytotoxicity and chemokine production by CD8βR CTL effectively reprograms the tumor microenvironment.
• Adoptively transferred CD8βR CTL can elicit durable, endogenous anti-tumor immunity capable of eradicating established tumors.